ARWR - Arrowhead Pharmaceuticals

-

$undefined

N/A

(N/A)

Arrowhead Pharmaceuticals NASDAQ:ARWR Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing.

Location: 177 E Colorado Blvd, Suite 700, California, 91105, US | Website: arrowheadpharma.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

2.368B

Cash

434.5M

Avg Qtr Burn

-87.89M

Short % of Float

8.20%

Insider Ownership

4.47%

Institutional Own.

80.49%

Qtr Updated

06/30/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Plozasiran (ARO-APOC3) Details
Familial chylomicronemia syndrome

NDA

Submission

Plozasiran (ARO-APOC3) Details
Severe hypertriglyceridemia

Phase 3

Data readout

Fazirsiran (ARO-AAT) (TAK-999) Details
Severe alpha-1 antitrypsin deficiency, Liver disease

Phase 3

Update

Phase 3

Initiation

Phase 2b

Update

ARO-ANG3 Details
Dyslipidemia

Phase 2

Update

ARO-CFB Details
Complement mediated diseases, Kidney disease, IgA nephropathy

Phase 1/2

Data readout

ARO-DM1 Details
Myotonic Dystrophy Type 1

Phase 1/2

Data readout

ARO-MMP7 Details
Idiopathic pulmonary fibrosis

Phase 1/2

Data readout

ARO-MUC5AC Details
Lung disease, Muco-Obstructive Lung Diseases

Phase 1/2

Data readout

ARO-C3 (RNAi) Details
Renal disease, Paroxysmal nocturnal hemoglobinuria

Phase 1/2

Data readout

ARO-RAGE Details
Muco-Obstructive Lung Diseases, Inflammatory disease, Asthma

Phase 1/2

Update

ARO-INHBE Details
Obesity, Metabolic disorder

Phase 1/2

Initiation

ARO-DUX4 Details
Facioscapulohumeral muscular dystrophy

Phase 1/2

Initiation

Failed

Discontinued

ARO-HSD Details
Liver disease, Non-alcoholic steatohepatitis

Failed

Discontinued